Csl Behring

This study follows 500 people with hemophilia B who received the gene therapy HEMGENIX to see how well it controls bleeding over time and if any safety issues arise. It also includes a group on standard factor IX treatment for comparison. The goal is to understand the real-world …

This study tests a drug called vamifeport in adults with hereditary hemochromatosis, a genetic condition that causes too much iron buildup in the body. The goal is to see if the drug can safely reduce iron stored in the liver. About 84 participants will receive either vamifeport …

This study follows 200 people with hereditary angioedema (HAE) who are starting a new medication called garadacimab. Researchers will track how often HAE attacks happen, how severe they are, and how the drug affects quality of life over 48 months. The goal is to see if the benefi…

This study tests a single-dose gene therapy called CSL222 in 20 adolescent boys (ages 12-17) with severe hemophilia B. The treatment aims to help the body produce its own clotting factor, reducing or stopping the need for regular infusions. Researchers will track bleeding rates a…

This program provides ongoing access to the study drug garadacimab for children aged 2 to 11 with hereditary angioedema (HAE) who completed a previous study and had good results. The goal is to keep preventing HAE attacks in these children. Only those who responded well and had n…

This study tests a new medicine (BE1116) to control bleeding in 200 adults undergoing complex heart surgery with a heart-lung machine. The medicine is compared to standard fresh frozen plasma. The goal is to see if BE1116 corrects clotting problems faster and reduces the need for…

This study tests a new drug called anumigilimab in 63 adults with sickle cell disease to see if it is safe. Participants receive weekly injections for 64 weeks, starting with a low dose that increases to their personal maximum. The goal is to reduce painful crises that often requ…

This study tests an inhaled medicine called CSL787 in adults with non-cystic fibrosis bronchiectasis, a lung condition that causes frequent infections and breathing problems. The goal is to see if CSL787 can delay the next serious lung flare-up and reduce how often they happen. A…

This study tests a one-time gene therapy called CSL222 for adults with severe or moderately severe hemophilia B who have detectable antibodies that might block treatment. The goal is to see if it reduces bleeding episodes. About 35 participants will receive a single dose and be m…

This study looks at two different doses of a medicine called Privigen in children aged 2 to 17 who have a nerve condition called CIDP. The goal is to see which dose works better to prevent the disease from getting worse. About 30 children will take part, and researchers will trac…

This study tests a medicine called fibrinogen concentrate (CSL511) to see if it controls bleeding better than the standard treatment (cryoprecipitate) during surgery for pseudomyxoma peritonei, a rare abdominal cancer. About 90 adults will be randomly assigned to receive one of t…

This study is testing an investigational drug called CSL300 to see if it can lower the risk of heart attacks and death in people with end-stage kidney disease who are on dialysis. The trial will enroll over 2,300 adults who have both kidney failure and either diabetes or known he…

This study tests an experimental drug called CSL889 in 70 adults and teens with sickle cell disease who are having a painful crisis. The drug is given through a vein and may help the crisis end faster. The main goals are to check safety and see how long it takes for pain to go aw…